OncoMax, Ltd. (“OncoMax”), a portfolio company of Russia-based Maxwell Biotech Venture Fund founded with the participation of Russian Venture Company announced today that it will be presenting the results of development of its lead product OM-RCA-01 at 4 major upcoming conferences on oncology.
The Director of Kidney Cancer Research Bureau and Chief Scientific Advisor of OncoMax Ilya Tsimafeyeu, M.D. will present the results of the drug development at the 8th Russian Congress of Oncologists “21st century Oncology – from the scientific researches to the clinical practice” (September 11-13, St. Petersburg), the European Cancer Congress ECCO-ESMO-ESTRO ( 27 September – 1 October, Amsterdam), the 17th Russian National Cancer Congress 2013 (November 12-14, Moscow), the European Multidisciplinary Meeting on Urological Cancers (November 15-17, Marseille).
Based on the results of the efficacy studies of the OM-RCA-01, monoclonal humanized antibody intended for the renal cell carcinoma treatment, Dr. Tsimafeyeu will present the latest achievements in the inhibition of the tumor angiogenesis.
The previous in vitro and in vivo studies have shown that the monoclonal humanized antibody OM-RCA-01 inhibits the cell proliferation and growth of the kidney cancer. It is very important to evaluate the effect of the drug on the other tumor component – angiogenesis i.e. the appearance of the vessels nourishing a tumor. The last study has proved that the OM-RCA-01 has antiangiogenic activity.
The drug can be prescribed both as first-line treatment and in case of inefficiency of other types of therapy in the second and subsequent lines.
The perspective of the medicine contributes not only to the proliferation of its information in the scientific community but also to the active development of the company’s patent portfolio which has recently been added by the U.S. patent (US 8487083 July 16, 201) on the invention referring to a monoclonal antibody specific to fibroblast growth factor receptor (FGFR1).